All In Biotech

Drug Trial Radar · NCT02542384

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of Intravenous CR845 in Patients Undergoing Abdominal Surgery

Last checked: Nov 19, 2026Latest source record: May 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 451 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

451

Actual

Start

Sep 2015

Primary completion

Apr 2018

Study completion Jun 2018

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study schedule is comprised of a 14-day Screening Period, a treatment period and an observation period. All eligible subjects will be randomized into one of 3 treatment groups (1 of 2 dose levels or matched placebo). Study drug CR845 will be administered intravenously prior to surgery, and at specific time intervals post surgery. Additional rescue pain and anti-nausea medication will be made available. Post surgical changes in pain intensity, nausea and vomiting will be assessed.

Conditions

  • Post Abdominal Surgery Pain

Interventions

  • CR845 IV 1 mcg/kgDrug

    CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours. Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.

  • CR845 IV 0.5 mcg/kgDrug

    CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours. Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.

  • Placebo IVDrug

    Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours. Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A comparison of the change in Pain Intensity over time using the Numeric Rating ScaleTime frame: 24 hours

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Sheffield, Alabama

  • Cara Therapeutics Study Site

    New Haven, Connecticut

  • Cara Therapeutics Study Site

    Bradenton, Florida

  • Cara Therapeutics Study Site

    Gainesville, Florida

  • Cara Therapeutics Study Site

    Maitland, Florida

  • Cara Therapeutics Study Site

    Miami Gardens, Florida

  • Cara Therapeutics Study Site

    Pensacola, Florida

  • Cara Therapeutics Study Site

    St. Petersburg, Florida

  • Cara Therapeutics Study Site

    Chicago, Illinois

  • Cara Therapeutics Study Site

    Boston, Massachusetts

  • Cara Therapeutics Study Site

    Camden, New Jersey

  • Cara Therapeutics Study Site

    Neptune City, New Jersey

  • Cara Therapeutics Study Site

    Durham, North Carolina

  • Cara Therapeutics Study Site

    Cleveland, Ohio

  • Cara Therapeutics Study Site

    Columbus, Ohio

  • Cara Therapeutics Study Site

    Pittsburgh, Pennsylvania

  • Cara Therapeutics Study Site

    Chattanooga, Tennessee

  • Cara Therapeutics Study Site

    Bellaire, Texas

  • Cara Therapeutics Study Site

    Fort Worth, Texas

  • Cara Therapeutics Study Site

    Houston, Texas

  • Cara Therapeutics Study Site

    Plano, Texas

  • Cara Therapeutics Study Site

    San Antonio, Texas

  • Cara Therapeutics Study Site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.